Alkahest Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Alkahest's estimated annual revenue is currently $12.2M per year.(i)
  • Alkahest's estimated revenue per employee is $155,000

Employee Data

  • Alkahest has 79 Employees.(i)
  • Alkahest grew their employee count by -26% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$72.3M4387%$564M$10.2B
Add Company

Alkahest is developing therapies derived from blood to treat neurological diseases, with an emphasis on age-related cognitive decline -- key medical challenges of our generation. The company's breakthrough research has demonstrated that factors in blood plasma of young mice are able to reverse brain deficits in normal aging and Alzheimer's disease models in mice. Clinical studies are being conducted in patients with different types of dementia and other neurodegenerative diseases. Alkahest is a private company based in San Carlos, CA, with investors including Barcelona, Spain-based Grifols, a global healthcare company and leading producer of plasma therapies, also a collaboration and commercialization partner.

keywords:N/A

N/A

Total Funding

79

Number of Employees

$12.2M

Revenue (est)

-26%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Alkahest's People

NameTitleEmail/Phone
1
Procurement ManagerReveal Email/Phone
2
Associate ScientistReveal Email/Phone
3
ScientistReveal Email/Phone
4
Chief Business OfficerReveal Email/Phone
5
ControllerReveal Email/Phone
6
Director, Clinical Data ManagementReveal Email/Phone
7
ScientistReveal Email/Phone
8
Director, TranscriptomicsReveal Email/Phone
9
ScientistReveal Email/Phone
10
Head Information TechnologyReveal Email/Phone

Alkahest News

2019-09-08 - High risks and high costs for young blood donations to older ...

In a randomized clinical study by the company, Alkahest, 39 patients intravenously received either 100 milliliters or 250 milliliters of the plasma ...

2019-09-03 - Protein Treatment Given Alzheimer's Patients in Phase 2 Trial ...

Alkahest's experimental blood-derived protein GRF6019 helps maintain cognition and function in mild to moderate Alzheimer's disease ...

2019-09-03 - Alkahest Initiates Phase 2 Clinical and Mechanistic Trial of ...

SAN CARLOS, Calif., Aug. 19, 2019 (GLOBE NEWSWIRE) -- Alkahest, Inc., a clinical stage biotechnology company focused on developing ...

2019-03-04 - As the FDA warns against ‘young blood,’ an ambitious Silicon Valley startup tests a cocktail for Alzheimer’s

SAN CARLOS, Calif. — The executives at Alkahest have heard plenty of vampire jokes. They are, after all, turning to blood from young donors in search of an elixir for diseases associated with aging. And yes, they’re in Silicon Valley. But this five-year-old biotech company led by Genentech alum ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$12.2M7932%N/A
#2
$12.6M8119%$65.1M
#3
$18M820%N/A
#4
$24.8M92-2%N/A
#5
$21.4M1022%N/A